a51070954.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of April 2015
Commission File Number: 001-06439
SONY CORPORATION
(Translation of registrant's name into English)
1-7-1 KONAN, MINATO-KU, TOKYO, 108-0075, JAPAN
(Address of principal executive offices)
The registrant files annual reports under cover of Form 20-F.
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F,
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934, Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-______
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
SONY CORPORATION
|
| |
(Registrant)
|
| |
|
| |
|
| |
By: /s/ Kenichiro Yoshida
|
| |
(Signature)
|
| |
Kenichiro Yoshida
|
| |
Executive Deputy President and
|
| |
Chief Financial Officer
|
Date: April 1, 2015
List of materials
Documents attached hereto:
i) Press release announcement: Sale of certain Olympus shares held by Sony Corporation
April 1, 2015
Sony Corporation
Sale of certain Olympus shares held by Sony Corporation
Sony Corporation (“Sony”) today announced that it has entered into a contract to sell 17,243,950 shares of its 34,487,900 shares of Olympus Corporation (“Olympus”) to JP Morgan Securities Japan Co., Ltd.
1. Purpose of the sale
Sony entered into this contract of sale to strengthen its financial resources and obtain funds for growth-oriented strategic investments. Following the sale, Sony plans to continue to closely collaborate with Olympus through its business alliance with Olympus and the medical business venture, Sony Olympus Medical Solutions Inc.
2. Summary of Olympus
|
Trade name
|
Olympus Corporation
|
|
Address of head office
|
Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo, Japan
|
|
Name and title of representative
|
Hiroyuki Sasa, Representative Director / President
|
|
Business
|
Manufacture and sale of precision machinery and instruments
|
|
Stated capital
|
124,520 million yen (as of March 31, 2014)
|
3. Summary of the buyer
|
Trade name
|
JP Morgan Securities Japan Co., Ltd.
|
|
Address of head office
|
Tokyo Building, 7-3, Marunouchi 2-chome, Chiyoda-ku, Tokyo, Japan
|
|
Name and title of representative
|
Steve Teru Rinoie, Representative Director, President and CEO
|
|
Business
|
Investment banking, fixed income, equities and other businesses; intermediary of global custody service and other asset servicing business
|
|
Stated capital
|
50,275 million yen (as of March 31, 2014)
|
4. Number of shares to be sold and number of shares to be held by Sony before/after the sale
|
Number of shares held by Sony before the sale
|
34,487,900 shares
(Number of voting rights: 344,879)
(Shareholding ratio: 10.06 %)
|
|
Number of shares to be sold
|
17,243,950 shares
(Number of voting rights: 172,439)
(Shareholding ratio: 5.03 %)
|
|
Number of shares to be held by Sony
|
17,243,950 shares
(Number of voting rights: 172,439)
(Shareholding ratio: 5.03 %)
|
5. Schedule
|
Execution of a contract of sale
|
April 1, 2015
|
|
Closing of the sale (Expected)
|
April 6, 2015
|
6. Outlook
In connection with the sale, Sony expects to record a gain on the sale of approximately 46.8 billion yen as other income during the first quarter for the fiscal year ending March 31, 2016. Sony will disclose the sale price of the shares on April 2, 2015 (JST) and will announce its forecast of the consolidated financial results for the fiscal year ending March 31, 2016 and its consolidated financial results for the fiscal year ended March 31, 2015 on April 30, 2015.
This press release is not an offer of securities for sale in the United States. The offer and sale of the shares have not been registered under the U.S. Securities Act, and the shares may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the U.S. Securities Act.